34 Lives Revenue and Competitors

West Lafayette , IN USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • 34 Lives's estimated annual revenue is currently $5.4M per year.(i)
  • 34 Lives's estimated revenue per employee is $155,000

Employee Data

  • 34 Lives has 35 Employees.(i)
  • 34 Lives grew their employee count by 133% last year.

34 Lives's People

NameTitleEmail/Phone
1
Co-Founder & CEOReveal Email/Phone
2
Co-Founder, Chief Commercial OfficerReveal Email/Phone
3
Chief Operating OfficerReveal Email/Phone
4
Director FinanceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.8M5-17%N/AN/A
#2
$5.7M376%N/AN/A
#3
$10.2M666%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$2M130%N/AN/A
#6
$7.6M49-2%N/AN/A
#7
$0.8M5-17%N/AN/A
#8
$7.9M516%N/AN/A
#9
$37.7M243-2%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is 34 Lives?

Every day in the US, approximately 34 patients are removed from the transplant waiting list either because they die or they become too sick to receive a transplant.\n\nOur mission is to bring that number down to zero by developing innovative technology and services that will extend the safe preservation times for unused kidneys.\n\nThe 34 Lives Leadership Team represents a combined 100+ years of experience in the fields of transplantation, healthcare, policy and technology.\n\nCEO Chris Jaynes developed the equipment and technology for ex-vivo or out-of-body lung assessment and is using his background and previous successes to also improve kidney transplantation.\n\nCCO and Co-founder Kathleen St. Jean built a 30-year career at Merck & Co., Inc., with a number of leadership roles in Sales, Professional Learning & Development and Customer Strategy.\n\nContact us at info@34lives.com

keywords:N/A

N/A

Total Funding

35

Number of Employees

$5.4M

Revenue (est)

133%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5M3552%N/A
#2
$5.2M36-12%N/A
#3
$7.8M3633%N/A
#4
$5.1M39-9%N/A
#5
$3.2M3926%N/A